PRTA250117C17500
- 0.80
- 0.000.00%
Prothena Newsroom
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $48
Leerink Partners Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $40
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Prothena Corp Analyst Ratings
B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Prothena Corp Analyst Ratings
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $24
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
Prothena's Strategic Advancements and Financial Strength Underpin Buy Rating
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Prothena(PRTA.US), With a Forecast Between $24 to $84
B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $31
HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target
Prothena Buy Rating Affirmed: Leadership Changes and Prasinezumab's Promise Signal Investment Opportunity